Finanzen von Rani Therapeutics Holdings Inc (RANI)RANIRani Therapeutics Holdings Inc

Evaluating the bottom line, Rani Therapeutics Holdings Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -516.86%, while the net margin is -493.03%. These profitability ratios, combined with a Return on Equity (ROE) of -179.10%, provide a clear picture of how effectively RANI converts its operational activities into shareholder value.

In the context of the broader market, RANI competes directly with industry leaders such as RLYB and COYA. With a market capitalization of $71.96M, it holds a significant position in the sector. When comparing efficiency, RANI's gross margin of 100.00% stands against RLYB's N/A and COYA's 100.00%. Such benchmarking helps identify whether Rani Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.

Rani Therapeutics has shown a gross margin of 100% in recent quarters, but it also has a significant net loss, with a net income of -$8.4 million in Q2 2026. The company has not generated consistent revenue, with total revenue fluctuating significantly across quarters.